Showing 6621-6630 of 9762 results for "".
- RINVOQ (Upadacitinib) Meets Primary Endpoint in Phase 2 Clinical Trial of Vitiligo, Program Advances to Phase 3https://practicaldermatology.com/news/upadacitinib-rinvoq-meets-primary-endpoint-in-phase-2-clinical-trial-of-vitiligo-program-advances-to-phase-3/2462064/Abbvie's upadacitinib (RINVOQ) met the primary endpoint of percent change from baseline in Facial Vitiligo Area Scoring Index (F-VASI) at week 24 with 11 mg and 22 mg doses versus placebo in adults with non-segmental vitiligo (NSV), according to data presented at the European Academy of Derma
- Topical NFX-179 Inhibits MEK Activity, May Prevents SCChttps://practicaldermatology.com/news/topical-nfx-179-inhibits-mek-activity-may-prevents-scc/2462063/Topical NFX-179 may prevent the development of cutaneous squamous cell carcinoma in pre-clinical models, according to a
- Study: Melanoma No Longer the Leading Cause of Skin Cancer Deathshttps://practicaldermatology.com/news/study-melanoma-no-longer-the-leading-cause-of-skin-cancer-deaths/2462062/Non-melanoma skin cancer (NMSC) is causing a greater number of global deaths than melanoma, according to a new study presented at the European Academy of Dermatology and Venerology (EADV) Congress 2023 in Berlin, Germany. Researchers also believe that NMSC is underreported and that the
- Incyte and Mandy Moore Partner to Empower People with AD in New Campaignhttps://practicaldermatology.com/news/incyte-and-mandy-moore-partner-to-empower-people-with-ad-in-new-campaign/2462060/Actress, singer and songwriter Mandy Moore is partnering with Incyte on
- EADV News: Almirall’s Ilumetri Improves Well-being of Pso Patients and Their Familieshttps://practicaldermatology.com/news/eadv-news-almiralls-ilumetri-improves-well-being-of-pso-patients-and-their-families/2462056/Ilumetri (tildrakizumab) significantly improves the well-being of psoriasis patients and their relatives, according to new data presented at the European Association of Dermatology and Venereology Congress 2023. Interim data from the POSITIVE study showed that tildrakizumab significantl
- One to Watch: AnaptysBio Inc.’s Imsidolimab (IL-36R) Shows Promise in GPPhttps://practicaldermatology.com/news/one-to-watch-imsidolimab-il-36r-shows-promise-in-gpp/2462052/AnaptysBio, Inc.’s Imsidolimab (IL-36R) performed well in in Generalized Pustular Psoriasis (GPP), according to topline results from the Phase 3 GEMINI-1 trial. Imsidolimab is an IgG4 antibody that inhibits the function of the interleukin-36 receptor (IL-36R),
- NPF Update: Group Hosts 25th Dermatology Residents’ Meeting and Research Symposium: A Cure for Allhttps://practicaldermatology.com/news/npf-update-group-hosts-25th-dermatology-residents-meeting-and-research-symposium-a-cure-for-all/2462049/The National Psoriasis Foundation (NPF) celebrated the 25th anniversary of the annual Dermatology Residents’ Meeting on October 7 and 8, 2023 in Washington, D.C. Experts and co-chairs Brad P. Glick, DO, MPH, FAAD, and Samuel Hwang MD, PhD. hosted the silver anniversary event with
- FDA Approves Novartis Cosentyx as First IV Formulation IL-17A Antagonist for PsAhttps://practicaldermatology.com/news/fda-approves-novartis-cosentyx-as-first-iv-formulation-il-17a-antagonist-for-psa/2462048/The US Food and Drug Administration (FDA) has approved an intravenous (IV) formulation of Novartis’ Cosentyx (secukinumab) for the treatment of adults with psoriatic arthritis (PsA), ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Cosentyx
- CDC Awards Grant to National Eczema Associationhttps://practicaldermatology.com/news/cdc-awards-grant-to-national-eczema-association/2462047/The National Eczema Association (NEA) was recently awarded a grant from the Centers for Disease Control and Pre
- Antibiotic-induced Acute Generalized Exanthematous Pustulosis: A Case Study of an 18-year-old Pregnant Female Presenting with Fever, Tachycardia, and Pustular Skin Eruptionhttps://practicaldermatology.com/news/antibiotic-induced-acute-generalized-exanthematous-pustulosis-a-case-study-of-an-18-year-old-pregnant-female-presenting-with-fever-tachycardia-and-pustular-skin-eruption/2462046/On the day of giving birth via vaginal delivery complicated by intrauterine fetal demise, an 18-year-old female, G1P000, developed preeclampsia with severe features. The patient subsequently developed chorioamnionitis and was started on ampicillin-gentamicin. After administration of the antibioti